Atea Pharmaceuticals (NASDAQ:AVIR) Stock Quotes, Forecast and News Summary

Q: What sector and industry does Atea Pharmaceuticals (AVIR) operate in?

Atea Pharmaceuticals is in the Health Care sector and Pharmaceuticals industry. They are listed on the NASDAQ.

Atea Pharmaceuticals Stock (NASDAQ: AVIR) stock price, news, charts, stock research, profile.

Open	$3.19
Close	$3.09
Volume / Avg.	309.14K / 413.49K
Day Range	$3.05 - $3.19
52 Wk Range	2.75 - 4.60
Market Cap	$260.99M
P/E Ratio	-
Dividend Yield	-
Exchange	NASDAQ
RSI	48
Short Interest	4.9%
Days to Cover	7.72

Recent News

After Failed COVID-19 Drug Trial, Atea Pharmaceuticals Touts Encouraging Data From Mid-Stage Hepatitis C Study

Atea Pharmaceuticals reports 98% SVR12 in a Phase 2 hepatitis C study, supporting an eight-week treatment plan with bemnifosbuvir and ruzasvir.

Vandana Singh

ZBH Gears Up for Q3 Earnings: What Lies Ahead for the Stock?

Zimmer Biomet Holdings, Inc. (NYSE: ZBH) is scheduled to report third-quarter 2024 results on Oct. 30, before market open.

Zacks

Atea Pharmaceuticals' COVID-19 Treatment Flunks In Late-Stage Study, Blames 'Constantly Evolving' Virus

Atea Pharmaceuticals' Phase 3 SUNRISE-3 trial for bemnifosbuvir in COVID-19 patients did not meet the primary endpoint. The company remains focused on its hepatitis C combination therapy.

Vandana Singh

Financials

Quarterly

Annual

Name

Revenue Change
Gross Change
EBITDA Change
EBIT Change
Earnings Change

Open	$3.19
Close	$3.09
Volume / Avg.	309.14K / 413.49K
Day Range	$3.05 - $3.19
52 Wk Range	2.75 - 4.60
Market Cap	$260.99M
P/E Ratio	-
Dividend Yield	-
Exchange	NASDAQ
RSI	48
Short Interest	4.9%
Days to Cover	7.72

About Atea Pharmaceuticals Inc

Sector

Health Care

Industry

Pharmaceuticals

Atea Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on discovering, devel...

Compare

EPS worse than industry

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

EPS worse than industry

FAQ

How do I buy Atea Pharmaceuticals (AVIR) stock?

You can purchase shares of Atea Pharmaceuticals (NASDAQ:AVIR) through any online brokerage.

View our list of the best stock brokerages

Who are Atea Pharmaceuticals (AVIR) competitors?

Other companies in Atea Pharmaceuticals’s space includes: Third Harmonic Bio (NASDAQ:THRD), Zevra Therapeutics (NASDAQ:ZVRA), Bioage Labs (NASDAQ:BIOA), Terns Pharma (NASDAQ:TERN) and Neumora Therapeutics (NASDAQ:NMRA).

What is the forecast, or price target, for Atea Pharmaceuticals (AVIR) stock?

Atea Pharmaceuticals has a consensus price target of $6.44.

What is the current price for Atea Pharmaceuticals (AVIR)?

The stock price for Atea Pharmaceuticals (NASDAQ: AVIR) is $3.09 last updated February 21, 2025 at 4:00 PM EST.

Does Atea Pharmaceuticals (AVIR) pay a dividend?

There are no upcoming dividends for Atea Pharmaceuticals.

When is Atea Pharmaceuticals (NASDAQ:AVIR) reporting earnings?

Atea Pharmaceuticals’s Q1 earnings are confirmed for Tuesday, May 13, 2025.

Is Atea Pharmaceuticals (AVIR) going to split?

There is no upcoming split for Atea Pharmaceuticals.

What sector and industry does Atea Pharmaceuticals (AVIR) operate in?

Atea Pharmaceuticals is in the Health Care sector and Pharmaceuticals industry. They are listed on the NASDAQ.

Comments

Atea Pharmaceuticals

Atea Pharmaceuticals (AVIR) Forecast